USAEUROPEViVE
ABOUTSPONSORSHIPFOUNDATION
Logo Hlth
Logo Hlth
05 May 2022 | 02:45 PM GMT

DTx in Mental Health: Pharma Opportunities

Participants:

Chandana Fitzgerald President, CommunityHLTH
Chandana Fitzgerald
President, CommunityHLTH
Aahuti Rai NED, Advisor & Venture PartnerFour Points Health | Conduit Connect
Aahuti Rai
NED, Advisor & Venture PartnerFour Points Health | Conduit Connect
Abhishek Shah Co-Founder & CEOWellthy Therapeutics Pvt. Ltd.
Abhishek Shah
Co-Founder & CEOWellthy Therapeutics Pvt. Ltd.
Ashley Mateus VP Consumer InsightsAkili Interactive Labs
Ashley Mateus
VP Consumer InsightsAkili Interactive Labs
Cathy Zaremba Director, Product MarketingBrightInsight
Cathy Zaremba
Director, Product MarketingBrightInsight
Chris Cera CEOArcweb Technologies
Chris Cera
CEOArcweb Technologies
Hannes Klöpper FounderHelloBetter
Hannes Klöpper
FounderHelloBetter
Jay Jung BDNaver Z Corp
Jay Jung
BDNaver Z Corp
Jeff Weness VP Growth and StrategyRefinedScience
Jeff Weness
VP Growth and StrategyRefinedScience
Katie Cannon Director - Strategic PartnershipsAvegen Health
Katie Cannon
Director - Strategic PartnershipsAvegen Health
Krys Zaluski Director, External GrowthBiogen
Krys Zaluski
Director, External GrowthBiogen
Lisa Kerr Senior Director, Patient ScienceAstraZeneca
Lisa Kerr
Senior Director, Patient ScienceAstraZeneca
Sarah Jackson Head of Business Development & Alliance MgmtClick Therapeutics
Sarah Jackson
Head of Business Development & Alliance MgmtClick Therapeutics
Tracy Lahey Strategy & Business Development ManagerAmgen
Tracy Lahey
Strategy & Business Development ManagerAmgen
Vasyl Pyrozhyk Vice PresidentSMBC
Vasyl Pyrozhyk
Vice PresidentSMBC
Vasyl Pyrozhyk Vice President - HealthcareSumitomo Mitsui Banking Corporation
Vasyl Pyrozhyk
Vice President - HealthcareSumitomo Mitsui Banking Corporation

About this Meeting

Over the past decade, DTx products have shown significant benefits in the management of mental health patients, not only for the treatment of mental health as the primary condition but also as secondary treatment in chronic diseases like cancer, psoriasis, etc. In this meeting we will focus on why pharma should take DTx solutions in mental health as an opportunity to improve their offerings. More specifically we will talk about: 

  • How can pharma leverage DTx to improve patients’ experience with psychiatric and non-psychiatric drugs (e.g. chemotherapy)?  
  • What is the ROI for pharma? Beyond financial reasons, what are the main drivers for pharma to incorporate DTx  solutions in their offerings for mental health? 
  • When is the right moment to incorporate the DTx product (during trials, promotion, or other)?  
  • Pharma requirements to partner: evidence, pricing, reimbursement, etc 
  • We have seen promising partnerships being formed in the last few years, such as, for instance, the collaboration between Happify Health and Almirall, as well as Click Therapeutics and Otsuka, and Gaia teaming up with Orexo. What are the results and key learnings of these partnerships so far?